Previous Close | 0.0017 |
Open | 0.0023 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0020 - 0.0023 |
52 Week Range | 0.0015 - 0.0096 |
Volume | |
Avg. Volume | 279,992 |
Market Cap | 756,364 |
Beta (5Y Monthly) | 2.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Potential of monetizing HPPD research by identifying biomarkers to identify individuals who have a higher risk of developing HPPD if they take psychedelicsMIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to announce it has completed the first phase of its series of studies with the University of Melbourne to determine the cause and possible cure for hallu
Ehave study "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder" approved by FDAMIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today that it received confirmation from the U.S. Food and Drug Administration ("FDA") that it
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve